<DOC>
	<DOC>NCT01430299</DOC>
	<brief_summary>The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort.</brief_summary>
	<brief_title>Efficacy and Safety of Accell Evo3 DBM in Instrumented Posterolateral Lumbar Spine Fusion</brief_title>
	<detailed_description />
	<mesh_term>Spondylosis</mesh_term>
	<criteria>Age 18 years of age or older at the time of surgery Require spinal fusion using posterior TLIF, PLF or PLIF in 1 to 3 levels between L3S1 Followup radiographic imaging post surgery Long term users of medications known to inhibit fusion,bone metabolism or epidural steroid injections Immunosuppressive agents, Disease Modifying Antirheumatic drugs (DMARDs) or any similar immunomodulating drugs, Growth Factors or Insulin Treated with radiotherapy since their surgery Medical conditions known to impact bone metabolism, such as Paget's disease, osteoporosis Pregnant or lactating women or women wishing to become pregnant Prisoner Participating in an investigational drug or another device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>